Department of Health Sciences, Faculty of Earth and Life Sciences, VU University Amsterdam, Amsterdam Public Health Research Institute, De Boelelaan 1085, 1081 HV, Amsterdam, The Netherlands.
Department of Obstetrics and Gynaecology, VU University Medical Centre, Amsterdam, The Netherlands.
Pharmacoeconomics. 2017 Oct;35(10):1007-1033. doi: 10.1007/s40273-017-0531-3.
The aim was to systematically review whether the reporting and analysis of trial-based cost-effectiveness evaluations in the field of obstetrics and gynaecology comply with guidelines and recommendations, and whether this has improved over time.
A literature search was performed in MEDLINE, the NHS Economic Evaluation Database (NHS EED) and the Health Technology Assessment (HTA) database to identify trial-based cost-effectiveness evaluations in obstetrics and gynaecology published between January 1, 2000 and May 16, 2017. Studies performed in middle- and low-income countries and studies related to prevention, midwifery, and reproduction were excluded.
Reporting quality was assessed using the Consolidated Health Economic Evaluation Reporting Standard (CHEERS) statement (a modified version with 21 items, as we focused on trial-based cost-effectiveness evaluations) and the statistical quality was assessed using a literature-based list of criteria (8 items). Exploratory regression analyses were performed to assess the association between reporting and statistical quality scores and publication year.
The electronic search resulted in 5482 potentially eligible studies. Forty-five studies fulfilled the inclusion criteria, 22 in obstetrics and 23 in gynaecology. Twenty-seven (60%) studies did not adhere to 50% (n = 10) or more of the reporting quality items and 32 studies (71%) did not meet 50% (n = 4) or more of the statistical quality items. As for the statistical quality, no study used the appropriate method to assess cost differences, no advanced methods were used to deal with missing data, and clustering of data was ignored in all studies. No significant improvements over time were found in reporting or statistical quality in gynaecology, whereas in obstetrics a significant improvement in reporting and statistical quality was found over time.
The focus of this review was on trial-based cost-effectiveness evaluations in obstetrics and gynaecology, so further research is needed to explore whether results from this review are generalizable to other medical disciplines.
The reporting and analysis of trial-based cost-effectiveness evaluations in gynaecology and obstetrics is generally poor. Since this can result in biased results, incorrect conclusions, and inappropriate healthcare decisions, there is an urgent need for improvement in the methods of cost-effectiveness evaluations in this field.
本研究旨在系统评价妇产科领域基于试验的成本效益评估的报告和分析是否符合指南和建议,以及是否随时间推移而有所改善。
在 MEDLINE、英国国家医疗服务体系经济评价数据库(NHS EED)和卫生技术评估(HTA)数据库中进行文献检索,以确定 2000 年 1 月 1 日至 2017 年 5 月 16 日发表的妇产科基于试验的成本效益评估。排除了中低收入国家开展的研究和与预防、助产及生殖相关的研究。
采用健康经济评估报告标准(CHEERS)声明(经修订,共 21 项,因为我们重点关注基于试验的成本效益评估)评估报告质量,并使用基于文献的标准清单(8 项)评估统计学质量。采用探索性回归分析评估报告和统计学质量评分与发表年份之间的相关性。
电子检索共得到 5482 项可能符合条件的研究。45 项研究符合纳入标准,其中 22 项为妇产科,23 项为妇科。27 项(60%)研究未符合 50%(n=10)或更多的报告质量条目,32 项研究(71%)未符合 50%(n=4)或更多的统计学质量条目。在统计学质量方面,没有研究使用适当的方法来评估成本差异,没有使用高级方法来处理缺失数据,并且所有研究都忽略了数据的聚类。没有发现妇科研究在报告或统计学质量方面随时间的显著改善,而在产科研究中,报告和统计学质量随时间的改善具有统计学意义。
本研究重点关注妇产科基于试验的成本效益评估,因此需要进一步研究以探索该综述结果是否可推广至其他医学学科。
妇产科基于试验的成本效益评估的报告和分析普遍较差。由于这可能导致结果存在偏差、得出错误的结论以及做出不适当的医疗保健决策,因此迫切需要改进该领域成本效益评估的方法。